Company commences Technegas trial in U.S.

11/20/2012 | ProactiveInvestors.co.au (Australia)

Cyclopharm has enrolled the first patient in a U.S. clinical trial involving its Technegas product, a gas inhaled by patients before imaging to improve detection of blood clots in the lungs. The multi-center study will eventually involve 750 patients and is expected to be completed in 18 months.

View Full Article in:

ProactiveInvestors.co.au (Australia)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC